# Phase 2 Carcinoma, Transitional Cell trials: 41 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 41 trials in phase 2 for Carcinoma, Transitional Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Carcinoma, Transitional Cell trials: 41 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/carcinoma-transitional-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 41
- Recruiting or not yet: 41
- Read on: November 19, 2026

## Trials

The 25 newest of 41, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07908979 | Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer | Fox Chase Cancer Center | Phase 2 | Recruiting | Bladder Cancer, Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma, Muscle-invasive Bladder Urothelial Carcinoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908979) |
| September 30, 2026 | NCT07848854 | Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples | Yunnan Cancer Hospital | Phase 2 | Recruiting | Bladder Cancer (BC), Urothelial Carcinoma (UC) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848854) |
| September 23, 2026 | NCT07837622 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | Urothelial Carcinoma (UC), Solid Tumors | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07837622) |
| July 21, 2026 | NCT07717242 | Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Recruiting | Bladder Urothelial Carcinoma, Bladder Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717242) |
| June 23, 2026 | NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) | Fudan University | Phase 2 | Not yet recruiting | Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662863) |
| June 15, 2026 | NCT07647289 | EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC | Peking University Third Hospital | Phase 2 | Recruiting | Muscle-Invasive Bladder Cancer (MIBC) | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647289) |
| June 11, 2026 | NCT07643519 | Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma | University of Florida | Phase 2 | Not yet recruiting | Urothelial Carcinoma (UC) | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643519) |
| June 9, 2026 | NCT07636772 | A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | Akeso | Phase 2 | Not yet recruiting | Urothelial Carcinoma (UC) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636772) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| April 1, 2026 | NCT07506057 | Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresectable Locally Advanced or... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Urothelial Carcinoma, Biliary Tract Cancer, HER2 | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07506057) |
| March 10, 2026 | NCT07460245 | Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 | Not yet recruiting | Urothelial Carcinoma | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460245) |
| January 7, 2026 | NCT07322263 | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC | Sponsor not shown (see the record) | Phase 2 | Recruiting | Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma, Carcinoma in Situ (CIS), High-Grade... | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322263) |
| January 2, 2026 | NCT07314723 | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Urothelial Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314723) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| November 21, 2025 | NCT07241793 | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial... | Sun Yat-sen University | Phase 2 | Recruiting | Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07241793) |
| October 29, 2025 | NCT07221942 | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma | Fox Chase Cancer Center | Phase 2 | Recruiting | Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Advanced Urothelial Carcinoma | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221942) |
| September 24, 2025 | NCT07189793 | Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase... | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder, Non-Muscle-Invasive Bladder... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189793) |
| September 19, 2025 | NCT07183319 | Circulating Tumor DNA Response In Urothelial Cancer | University of Oklahoma | Phase 2 | Recruiting | Urothelial Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07183319) |
| June 29, 2025 | NCT07043972 | Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma | Fox Chase Cancer Center | Phase 2 | Recruiting | Urothelial Carcinoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07043972) |
| May 21, 2025 | NCT06983210 | Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma | Nagoya University | Phase 2 | Recruiting | Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra... | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983210) |
| February 12, 2025 | NCT06823427 | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 | Recruiting | Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06823427) |
| November 19, 2024 | NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Jazz Pharmaceuticals | Phase 2 | Recruiting | Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06695845) |
| November 12, 2024 | NCT06683846 | Ivonescimab in the Treatment of Multiple Advanced Tumors | Fudan University | Phase 2 | Recruiting | Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary, Renal Angiomyolipoma, Perivascular... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06683846) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 3 |
| Fox Chase Cancer Center | 3 |
| Mayo Clinic | 2 |
| National Cancer Institute (NCI) | 2 |
| [Mabwell (Shanghai) Bioscience Co., Ltd.](https://specstream.ai/data/clinical-trials/company/mabwell-shanghai-bioscience-co-ltd) | 2 |
| Fudan University | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| University of Florida | 2 |
| Erasmus Medical Center | 1 |
| Yunnan Cancer Hospital | 1 |
| Sun Yat-sen University | 1 |
| University of California, Irvine | 1 |
| Centre Francois Baclesse | 1 |
| [Abbisko Therapeutics Co, Ltd](https://specstream.ai/data/clinical-trials/company/abbisko-therapeutics-co-ltd) | 1 |
| Spanish Oncology Genito-Urinary Group | 1 |
| University of Oklahoma | 1 |
| [Seagen, a wholly owned subsidiary of Pfizer](https://specstream.ai/data/clinical-trials/company/seagen-a-wholly-owned-subsidiary-of-pfizer) | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Peking University Third Hospital | 1 |
| University of Michigan Rogel Cancer Center | 1 |
| Gruppo Oncologico Italiano di Ricerca Clinica | 1 |
| Nagoya University | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| [Jazz Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/jazz-pharmaceuticals) | 1 |
| [Akeso](https://specstream.ai/data/clinical-trials/company/akeso) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 15 |
| Italy | 3 |
| Spain | 3 |
| France | 2 |
| United Kingdom | 2 |
| Canada | 2 |
| Japan | 2 |
| Netherlands | 1 |
| Puerto Rico | 1 |
| Argentina | 1 |
| Australia | 1 |
| Belgium | 1 |
| Chile | 1 |
| Israel | 1 |
| Turkey (Türkiye) | 1 |
| Uganda | 1 |
| Georgia | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
- [Dumpster rental companies in the United States](https://specstream.ai/data/businesses/dumpster-rental-companies/united-states)
- [T-shirt printers in the United States](https://specstream.ai/data/businesses/t-shirt-printers/united-states)
- [Home health care agencies in the United States](https://specstream.ai/data/businesses/home-health-care-agencies/united-states)
- [Appliance repair companies in the United States](https://specstream.ai/data/businesses/appliance-repair-companies/united-states)
- [Metal suppliers in the United States](https://specstream.ai/data/businesses/metal-suppliers/united-states)
